NO20016053L - IL-8 receptor antagonists - Google Patents

IL-8 receptor antagonists

Info

Publication number
NO20016053L
NO20016053L NO20016053A NO20016053A NO20016053L NO 20016053 L NO20016053 L NO 20016053L NO 20016053 A NO20016053 A NO 20016053A NO 20016053 A NO20016053 A NO 20016053A NO 20016053 L NO20016053 L NO 20016053L
Authority
NO
Norway
Prior art keywords
receptor antagonists
antagonists
receptor
Prior art date
Application number
NO20016053A
Other languages
Norwegian (no)
Other versions
NO20016053D0 (en
Inventor
Katherine Louisa Widdowson
Daniel Frank Veber
Anthony Joseph Jurewicz
Melvin C Rutledge
Robert Philip Hertzberg
Gregory Martin Benson
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20016053D0 publication Critical patent/NO20016053D0/en
Publication of NO20016053L publication Critical patent/NO20016053L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Quinoline Compounds (AREA)
NO20016053A 1999-06-16 2001-12-11 IL-8 receptor antagonists NO20016053L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13967599P 1999-06-16 1999-06-16
PCT/US2000/016499 WO2000076495A1 (en) 1999-06-16 2000-06-15 Il-8 receptor antagonists

Publications (2)

Publication Number Publication Date
NO20016053D0 NO20016053D0 (en) 2001-12-11
NO20016053L true NO20016053L (en) 2001-12-11

Family

ID=22487790

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20016053A NO20016053L (en) 1999-06-16 2001-12-11 IL-8 receptor antagonists

Country Status (20)

Country Link
EP (1) EP1185261A4 (en)
JP (1) JP2003501459A (en)
KR (1) KR20020010709A (en)
CN (1) CN1355697A (en)
AR (1) AR030391A1 (en)
AU (1) AU766083B2 (en)
BR (1) BR0010802A (en)
CA (1) CA2377341A1 (en)
CO (1) CO5200760A1 (en)
CZ (1) CZ20014471A3 (en)
HK (1) HK1044483A1 (en)
HU (1) HUP0201571A3 (en)
IL (1) IL145761A0 (en)
MX (1) MXPA01013004A (en)
NO (1) NO20016053L (en)
NZ (1) NZ514695A (en)
PL (1) PL352232A1 (en)
TR (1) TR200103680T2 (en)
WO (1) WO2000076495A1 (en)
ZA (1) ZA200109479B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521479B2 (en) * 2001-04-16 2009-04-21 Panacea Pharmaceuticals, Inc. Methods of treating prion disease in mammals
GB0201882D0 (en) * 2002-01-28 2002-03-13 Novartis Ag Organic compounds
US20060058395A1 (en) * 2002-08-01 2006-03-16 Neurosearch A/S Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy
CN1984899B (en) * 2004-05-12 2011-07-27 先灵公司 CXCR1 and CXCR2 chemokine antagonists
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
TW200600492A (en) 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
CA2580690A1 (en) 2004-10-21 2006-05-04 Transtech Pharma, Inc. Bissulfonamide compounds as agonists of galr1, compositions, and methods of use
AU2006206611A1 (en) 2005-01-19 2006-07-27 Bristol-Myers Squibb Company 2-phenoxy-N- (1, 3 , 4-thiadizol-2-yl) pyridin-3-amine derivatives and related compounds as P2Y1 receptor inhibitors for the treatment of thromboembolic disorders
WO2006089871A2 (en) * 2005-02-23 2006-08-31 Neurosearch A/S Diphenylurea derivatives useful as erg channel openers for the treatment of cardiac arrhythmias
ATE502924T1 (en) 2005-06-27 2011-04-15 Bristol Myers Squibb Co LINEAR UREA MIMETIC ANTAGONISTS OF THE P2Y1 RECEPTOR FOR THE TREATMENT OF THROMBOSIS
KR20080027890A (en) 2005-06-27 2008-03-28 브리스톨-마이어스 스큅 컴퍼니 N-linked heterocyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
ES2352796T3 (en) 2005-06-27 2011-02-23 Bristol-Myers Squibb Company CYCLIC ANTAGONISTS UNITED TO C OF THE P2Y1 RECEIVER USEFUL IN THE TREATMENT OF THROMBOTHIC AFFECTIONS.
WO2007002634A1 (en) 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
JP2008184403A (en) * 2007-01-29 2008-08-14 Japan Health Science Foundation New hepatitis c virus inhibitor
KR100982661B1 (en) * 2008-04-22 2010-09-17 전남대학교산학협력단 Pharmaceutical composition for the prevention and treatment of malaria containing a compound that inhibits plasmincin II activity as an active ingredient and a method for treating malaria using the same
KR100970940B1 (en) * 2010-05-03 2010-07-20 전남대학교산학협력단 Pharmaceutical composition for preventing and treating malaria comprising compounds that inhibit Plasmepsin II activity and the method of treating malaria using thereof
US10093617B1 (en) 2015-10-30 2018-10-09 Sumitomo Chemical Company, Limited Method for producing 2-amino-4-substituted phenol

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA921120B (en) * 1991-02-19 1993-01-27 Smithkline Beecham Corp Cytokine inhibitors
WO1996025157A1 (en) * 1995-02-17 1996-08-22 Smithkline Beecham Corporation Il-8 receptor antagonists
WO2000016768A1 (en) * 1998-09-18 2000-03-30 Smithkline Beecham Corporation Cxcr2 inhibitors and pmn adhesion and t-cell chemotaxis

Also Published As

Publication number Publication date
EP1185261A4 (en) 2004-02-25
NO20016053D0 (en) 2001-12-11
JP2003501459A (en) 2003-01-14
TR200103680T2 (en) 2002-07-22
AU5741300A (en) 2001-01-02
CN1355697A (en) 2002-06-26
HUP0201571A2 (en) 2002-08-28
CZ20014471A3 (en) 2002-08-14
IL145761A0 (en) 2002-07-25
AR030391A1 (en) 2003-08-20
BR0010802A (en) 2002-02-19
HK1044483A1 (en) 2002-10-25
MXPA01013004A (en) 2002-07-30
KR20020010709A (en) 2002-02-04
EP1185261A1 (en) 2002-03-13
WO2000076495A1 (en) 2000-12-21
ZA200109479B (en) 2002-11-18
CA2377341A1 (en) 2000-12-21
CO5200760A1 (en) 2002-09-27
HUP0201571A3 (en) 2002-11-28
PL352232A1 (en) 2003-08-11
AU766083B2 (en) 2003-10-09
NZ514695A (en) 2004-05-28

Similar Documents

Publication Publication Date Title
NO20001100D0 (en) IL-8 receptor antagonists
NO20025754D0 (en) IL-8 Receptor Antagonists
DE60216229D1 (en) IL-8 receptor antagonists
NO20016053L (en) IL-8 receptor antagonists
ATE299698T1 (en) IL-8 RECEPTOR ANTAGONISTS
ATE353215T1 (en) IL-8 RECEPTOR ANTAGONISTS
NO20016052D0 (en) IL-8 receptor antagonists
ATE381330T1 (en) IL-8 RECEPTOR ANTAGONISTS
NO20024554D0 (en) IL-8 receptor antagonists
DK1180028T3 (en) IL-8 receptor antagonists
ATE303370T1 (en) IL-8 RECEPTOR ANTAGONISTS
DE69824837D1 (en) IL-8 RECEPTOR ANTAGONISTS
NO20015774D0 (en) IL-8 receptor antagonists
NO20024367L (en) IL-8 receptor antagonists
NO20016065L (en) IL-8 receptor antagonists
NO20016102L (en) IL-8 receptor antagonists
NO20024366D0 (en) IL-8 receptor antagonists
NO20010353L (en) IL-8 receptor antagonist
SE0003996D0 (en) receptor Antagonists

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application